Brief: Celyad Oncology Provides Updates On CYAD-211, CYAD-01 And CYAD-02

Celyad Oncology SA

07/12/2020 06:08

Dec 7 (Reuters) - CELYAD ONCOLOGY  CYAD.BR :
    * CELYAD ONCOLOGY PROVIDES UPDATES ON ALLOGENEIC AND
AUTOLOGOUS
CAR T PROGRAMS AT 62ND ASH ANNUAL MEETING AND EXPOSITION
    * COMPANY DISCONTINUES DEVELOPMENT OF FIRST-GENERATION,
AUTOLOGOUS
CAR T CANDIDATE CYAD-01 BASED ON CLINICAL FUTILITY OBSERVED TO
DATE FROM PHASE 1 THINK TRIAL
    * PRECLINICAL RESULTS FOR CYAD-211 FOR MULTIPLE MYELOMA
SHOWED
ROBUST ANTITUMOR ACTIVITY
    * PRECLINICAL RESULTS FOR CYAD-211 FOR MULTIPLE MYELOMA
SHOWED NO
DEMONSTRABLE EVIDENCE OF GRAFT-VERSUS-HOST DISEASE

Source text for Eikon:  ID:nGNX5lF2Bm 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))